Annika Schaefer

List of Publications by Year in Descending Order

35 papers	1,856 citations	20 h-index	36 g-index
36 ext. papers	2,385 ext. citations	11.9 avg, IF	4.33 L-index

#	Paper	IF	Citations
35	Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer.. *Lancet, The*, **2022**,	40	9
34	COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety.. *Nature Reviews Clinical Oncology*, **2022**,	19.4	16
33	Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer.. *Cancer Cell*, **2021**,	24.3	10
32	Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study.. *Nature Cancer*, **2021**, 2, 1321-1337	15.4	17
31	Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study.. *Nature Cancer*, **2021**, 2, 1321-1337	15.4	24
30	Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. *Cancer Cell*, **2021**, 39, 1497-1518.e11	24.3	14
29	Selection of metastasis competent subclones in the tumour interior. *Nature Ecology and Evolution*, **2021**, 5, 1033-1045	12.3	13
28	Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2. *Nature Medicine*, **2021**, 27, 1362-1366	50.5	26
27	Spatial patterns of tumour growth impact clonal diversification in a computational model and the TRACERx Renal study.. *Nature Ecology and Evolution*, **2021**,	12.3	4
26	Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue. *Cell Reports*, **2020**, 31, 107550	10.6	19
25	Inhibiting WNT and NOTCH in renal cancer stem cells and the implications for human patients. *Nature Communications*, **2020**, 11, 929	17.4	46
24	Cancer, COVID-19, and Antiviral Immunity: The CAPTURE Study. *Cell*, **2020**, 183, 4-10	56.2	23
23	Identification of miR-21-5p and miR-210-3p serum levels as biomarkers for patients with papillary renal cell carcinoma: a multicenter analysis. *Translational Andrology and Urology*, **2020**, 9, 1314-1322	2.3	7
22	Circular RNAs and Their Linear Transcripts as Diagnostic and Prognostic Tissue Biomarkers in Prostate Cancer after Prostatectomy in Combination with Clinicopathological Factors. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	3
21	Instability of circular RNAs in clinical tissue samples impairs their reliable expression analysis using RT-qPCR: from the myth of their advantage as biomarkers to reality. *Theranostics*, **2020**, 10, 9268-9279	12.1	8
20	Circular RNAs in Clear Cell Renal Cell Carcinoma: Their Microarray-Based Identification, Analytical Validation, and Potential Use in a Clinico-Genomic Model to Improve Prognostic Accuracy. *Cancers*, **2019**, 11,	6.6	26
19	A Novel Predictor Tool of Biochemical Recurrence after Radical Prostatectomy Based on a Five-MicroRNA Tissue Signature. *Cancers*, **2019**, 11,	6.6	13

18	miR-9-5p in Nephrectomy Specimens is a Potential Predictor of Primary Resistance to First-Line Treatment with Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell Carcinoma. *Cancers* , **2018**, 10,	6.6	10
17	Circular RNAs: a new class of biomarkers as a rising interest in laboratory medicine. *Clinical Chemistry and Laboratory Medicine*, **2018**, 56, 1992-2003	5.9	16
16	The translational potential of microRNAs as biofluid markers of urological tumours. *Nature Reviews Urology*, **2016**, 13, 734-752	5.5	81
15	Diagnostic and prognostic potential of circulating cell-free genomic and mitochondrial DNA fragments in clear cell renal cell carcinoma patients. *Clinica Chimica Acta*, **2016**, 452, 109-19	6.2	43
14	Piwi-interacting RNAs as novel prognostic markers in clear cell renal cell carcinomas. *Journal of Experimental and Clinical Cancer Research*, **2015**, 34, 61	12.8	70
13	MicroRNA signature helps distinguish early from late biochemical failure in prostate cancer. *Clinical Chemistry*, **2013**, 59, 1595-603	5.5	46
12	The antiapoptotic function of miR-96 in prostate cancer by inhibition of FOXO1. *PLoS ONE*, **2013**, 8, e80807	3.7	60
11	MicroRNAs as new diagnostic and prognostic biomarkers in urological tumors. *Critical Reviews in Oncogenesis*, **2013**, 18, 289-302	1.3	18
10	The miRNA-kallikrein axis of interaction: a new dimension in the pathogenesis of prostate cancer. *Biological Chemistry*, **2012**, 393, 379-89	4.5	28
9	MiR-133b targets antiapoptotic genes and enhances death receptor-induced apoptosis. *PLoS ONE*, **2012**, 7, e35345	3.7	74
8	miRNAs can predict prostate cancer biochemical relapse and are involved in tumor progression. *International Journal of Oncology*, **2011**, 39, 1183-92	4.4	30
7	Reference genes for the relative quantification of microRNAs in renal cell carcinomas and their metastases. *Analytical Biochemistry*, **2011**, 417, 233-41	3.1	75
6	MicroRNAs as regulators of signal transduction in urological tumors. *Clinical Chemistry*, **2011**, 57, 954-68	5.5	97
5	Suitable reference genes for relative quantification of miRNA expression in prostate cancer. *Experimental and Molecular Medicine*, **2010**, 42, 749-58	12.8	89
4	MicroRNAs and cancer: current state and future perspectives in urologic oncology. *Urologic Oncology: Seminars and Original Investigations*, **2010**, 28, 4-13	2.8	65
3	Diagnostic, prognostic and therapeutic implications of microRNAs in urologic tumors. *Nature Reviews Urology*, **2010**, 7, 286-97	5.5	88
2	Robust microRNA stability in degraded RNA preparations from human tissue and cell samples. *Clinical Chemistry*, **2010**, 56, 998-1006	5.5	224
1	Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. *International Journal of Cancer*, **2010**, 126, 1166-76	7.5	464